Zura Bio reports Q2 2026 results, completes enrollment in two tibulizumab trials
The company finished enrollment ahead of target in both mid-stage tibulizumab studies and plans a third trial in polymyalgia rheumatica by year-end 2026.
Zura Bio Limited (Nasdaq: ZURA) announced second quarter 2026 financial results and pipeline updates on August 11, 2026. The Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa completed and exceeded enrollment with 247 participants, with topline data anticipated in the fourth quarter of 2026.1 The Phase 2 TibuSURE study in systemic sclerosis also completed and exceeded enrollment with 91 participants, with topline data anticipated in the first half of 2027.1
Zura has selected polymyalgia rheumatica (PMR) as a third indication for tibulizumab and plans to start a Phase 2 study called NEXUS-PMR by year end 2026. The company described PMR as a common inflammatory rheumatic disease affecting older adults, marked by disabling pain and stiffness in the shoulders and hips, for which options beyond long-term steroid use are limited1. Zura said that more than 700,000 people in the U.S. currently have the condition, and that under existing standard of care most patients remain dependent on steroids, with treatment typically lasting around six years before permanent discontinuation becomes possible1. Zura has engaged with the FDA and received feedback that was constructive and supportive of the Company's proposed development strategy.1 The company is also continuing to weigh development paths for two other candidates, torudokimab (ZB‑880) and crebankitug (ZB‑168), informed by current clinical and translational evidence and ongoing assessment of the evolving competitive landscape1.
On the financial side, Zura reported cash and cash equivalents of $205.1 million as of June 30, 2026, which it expects will be sufficient to support planned operations through at least the end of 2028.1 Research and development spending rose to $20.7 million for the quarter from $8.7 million a year earlier, which the company attributed primarily to advancement of its Phase 2 tibulizumab clinical programs.1 General and administrative expenses declined to $8.6 million from $9.4 million, which the company attributed to lower expense in professional fees.1 Net loss for the quarter was $26.3 million, or $0.21 per share, compared with $16.0 million, or $0.17 per share, in the same period of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.